Navigation Links
Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results
Date:8/13/2009

2 million, or $1.09 per share, compared to a net loss of $18.2 million, or $1.23 per share, for fiscal 2008.

Cash, cash equivalents and investments at June 30, 2009 were $5.3 million, compared to $8.4 million at March 31, 2009 and $23.3 million at June 30, 2008. As of June 30, 2009, Cardica had approximately 15.8 million common shares outstanding.

Milestones for Fiscal 2010

Cardica expects to achieve the following milestones over the course of fiscal 2010:

  • Begin selling C-Port(R) X-CHANGEII(TM);
  • Build a sales organization of 25 to 30 total sales representatives, including a direct salesforce, independent distributors and manufacturer's representatives, to support the sales effort for the C-Port and PAS-Port systems;
  • Complete animal testing of the Cardica Microcutter for general and thoracic surgery;
  • Complete tooling of Cardica Microcutter; and
  • Achieve additional milestones under Cardica's agreement with Cook for the development of a closure device for patent foramen ovale.

Financial Guidance for 2010

As Cardica transitions its cardiac surgery business to a small core direct sales force supported by independent distributors and manufacturer's representatives, Cardica is not able to provide product revenue guidance for fiscal 2010. For fiscal 2010, Cardica expects that research and development and sales, general and administrative expenses will total between $11 and $13 million, including non-cash stock-based compensation expense of approximately $1 million. Cardica expects its cash and cash equivalents to decline by approximately $2.5 million per quarter in fiscal 2010, without giving effect to any financing transactions.

Conference Call Details

Cardica's management will host a conference call today, August 13, 2009, at 4:30
'/>"/>

SOURCE Cardica, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Cardica Announces Proposed Public Offering of Common Stock
2. Cardica Announces Pricing of $34.7 Million Public Offering of Common Stock
3. Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
4. Cardica Announces Exercise of Over-Allotment Option
5. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
6. Cardicas C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University
7. Cardicas C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study
8. Cardica to Announce Fiscal 2008 Third Quarter Financial Results on Tuesday, April 29, 2008
9. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
10. Renowned Leader and Educator in Robotic Cardiac Bypass Surgery Leverages Cardicas C-Port(R) Flex-A(R) Anastomosis System in His Practice and to Educate Cardiothoracic Surgeons
11. Cardica Names Frederick Bauer Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... (PRWEB) November 27, 2014 Now that ... season has officially launched, Emassagechair.com has announced ... Monday Discount Event. , Negotiating on behalf of ... top massage chair brands, Emassagechair.com has generated significant buzz ... deals and biggest discounts yet. , Shoppers are excited ...
(Date:11/27/2014)... VogueQueen.com is making every effort to offer more affordable ... the premier online supplier of elegant special occasion dresses ... huge selection of sexy prom dresses today. In addition ... many beautiful styles in its product line. Click to ... , “VogueQueen.com hopes to provide a truly unique shopping ...
(Date:11/27/2014)... Aliso Viejo, California (PRWEB) November 27, 2014 ... have announced a new plugin entitled ProPip, taking FCPX to ... picture in picture effect with a few clicks of a ... is a time saver that our users will appreciate.” , ... with full customization leaving the possibilities truly endless. ProPip is ...
(Date:11/27/2014)... 2014 HealthPostures, a leading ... , has announced that it has entered into ... The partnership will put HealthPostures' products into central ... In addition to having its products sold through ... HealthPostures' products with the business decision makers in ...
(Date:11/27/2014)... At The Little Gym, we know ... as no surprise when a recent study confirmed that ... The Journal of Pediatrics found that “Promoting ... during the school years may be important not only ... study monitored two groups of children; those that were ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... pediatric combination for, immunization against diphtheria, tetanus, pertussis, polio and ... ... Pa. and LYON, France, June 23 Sanofi,Pasteur, the vaccines ... and Drug Administration (FDA) has licensed Pentacel(R),Diphtheria and Tetanus Toxoids ...
... decrease in health care and compensation benefits, ... economy, employers are managing to maintain a balance ... Survey released today by,the Society for Human Resource ... health care costs, combined with the state of ...
... NEW YORK, June 21 Many professionals,world-wide are calling ... force fluoridation on almost the whole state. SB 312 ... most Louisianans knowing,it was happening. The professionals are asking ... Citizens should have been part of this discussion,but they ...
... DELHI, India, June 20 The United States,has ... Save the Children to assist people affected by ... Shortages have emerged in recent months because ... in rapidly growing rat infestations in,crop-growing areas. With ...
... San Francisco,Medical Society (SFMS) announces the "David Perlman ... is presented each January at,the SFMS Annual Dinner ... television, radio and newspapers and magazines. The deadline ... award., A prestigious panel of SFMS journalists, ...
... life is greatly improved, too, , , FRIDAY, June 20 ... for many people with kidney disease, it can be ... blood as effectively as well-functioning kidneys do. , But, ... to change all that. , Nocturnal dialysis, not surprisingly, ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Despite Economic Downturn, Employee Benefits Remain Stable in 2008 2Health News:Professionals Ask Governor Jindal to Veto Unfair Fluoridation Bill 2Health News:SFMS David Perlman Award For Excellence in Medical/Health Reporting Recognizes Local Reporters 2Health News:Nocturnal Dialysis: A Better Way to Kidney Health 2Health News:Nocturnal Dialysis: A Better Way to Kidney Health 3
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... MINNEAPOLIS, Sept. 29 ProUroCare Medical Inc. (OTC Bulletin ... imaging products, today announced the signing of an agreement ... LP of Juno Beach, Fla.  The proceeds of the ... portfolio and to support scale-up activities associated with final ...
... PROSPECT, Ill., Sept. 29 Earlier this year, the National ... was introduced to the AWARxE campaign, which was created and ... the power of the campaign, NABP obtained the AWARxE program ... level. The Foundation was inspired to create ...
Cached Medicine Technology:UPDATE - ProUroCare Announces $3 Million Financing Agreement 2UPDATE - ProUroCare Announces $3 Million Financing Agreement 3NABP Purchases AWARxE Consumer Protection Program 2
The CIC Pro Clinical Information Center brings together vital patient information from multiple monitoring devices....
... Alaris System integrates drug infusion,with patient ... a single, modular platform. With multiple ... modules as you,need them, keeping the ... a minimum while managing the unique ...
... Gemini Family of infusion pumps ... a collective series of administration ... line offers a wide variety ... sets, each featuring the patented ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
Medicine Products: